SCHEMBL5492004

SCHEMBL5492004

Fc1ccc(-c2ccc3nc(NCCc4ccccn4)ncc3c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.48
MAPK8 P45983 1/20 0.48
HTR2C P28335 1/20 0.47
HTR7 P34969 1/20 0.47
RPS6KB1 P23443 2/20 0.43
CYP1A2 P05177 1/20 0.43
FGFR1 P11362 1/20 0.43
HTT P42858 1/20 0.42
GBA1 P04062 1/20 0.42
CNR2 P34972 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2B Q13224 1/20 0.42
CTNNB1 P35222 1/20 0.42
TCF7L2 Q9NQB0 1/20 0.42
BRD4 O60885 1/20 0.41
OGA O60502 1/20 0.40
IGF1R P08069 1/20 0.40
ACP1 P24666 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5497134 0.92 MAPK8 (0.45) NAMPTMAPK8HTR2CHTR7RPS6KB1
SCHEMBL5490633 0.92 GBA1 (0.47) MAPK8RPS6KB1CYP1A2FGFR1GBA1
SCHEMBL5496788 0.88 MAPK8 (0.49) NAMPTMAPK8HTR2CHTR7RPS6KB1
SCHEMBL5495502 0.88 MAPK8 (0.51) NAMPTMAPK8HTR2CHTR7RPS6KB1
SCHEMBL5488816 0.87 KDM4E (0.46) NAMPTMAPK8HTR2CHTR7RPS6KB1
SCHEMBL5498308 0.87 MAPK8 (0.47) NAMPTMAPK8HTR2CHTR7RPS6KB1
SCHEMBL5489127 0.84 FGFR1 (0.44) NAMPTMAPK8HTR2CHTR7RPS6KB1
SCHEMBL5491332 0.83 BRD4 (0.43) MAPK8RPS6KB1CYP1A2FGFR1GBA1
SCHEMBL5498053 0.83 BRD4 (0.43) MAPK8RPS6KB1CYP1A2FGFR1GBA1
SCHEMBL5494839 0.82 FGFR1 (0.52) MAPK8CYP1A2FGFR1GBA1OGA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP claimed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 EP claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US claimed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 WO claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 NAMPT 829/4885MAPK8 200/4885HTR2C 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.